Abstract
Asal Pilehvari, Qingyi He, Gretchen Kimmick, Roger Anderson
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Breast cancer statistics, 2023
2023
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008–2017 ESME cohort
10.1016/j.esmoop.2021.100114 · 2021
Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center
10.1007/s00432-020-03184-z · 2020
The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: a population-based study in British Columbia from 2003 to 2013
10.1002/cncr.32631 · 2020
How not to neglect the care of elderly breast cancer patients?
10.1016/j.breast.2011.03.003 · 2011
Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology
2017
The prevalence and outcomes of frailty in older cancer patients
2015
Practical assessment and management of vulnerabilities in older patients receiving chemotherapy
10.1200/jco.2018.78.8687 · 2018
Geriatric assessment improves prediction of surgical outcomes in older adults undergoing cancer surgery
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
2012
Frailty in relation to the accumulation of deficits
10.1093/gerona/62.7.722 · 2007
Frailty in elderly people
10.1016/s0140-6736(12)62167-9 · 2013
Disparities in breast cancer and African ancestry: a global perspective
2022
Disparities in cancer outcomes: perspectives and future directions
2021
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer
10.1038/s41523-023-00595-2 · 2023
Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting
10.1186/s13058-024-01902-w · 2024
Race, breast cancer subtypes, and survival in the Carolina breast cancer study
10.1001/jama.295.21.2492 · 2006
The impact of comorbidity on cancer and its treatment
2016
Using claims data to predict dependency in activities of daily living as a proxy for frailty
10.1002/pds.3719 · 2015
Socioeconomic status is associated with frailty: the Women’s Health and Aging Studies
10.1136/jech.2008.078428 · 2010
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population
2002
Controlling for frailty in pharmacoepidemiologic studies of older adults: validation of an existing Medicare claims-based algorithm
10.1097/ede.0000000000000833 · 2018
Male-female wage differentials in urban labor markets
10.2307/2525981 · 1973
Unconditional quantile regressions
10.3982/ecta6822 · 2009
Disparities in disease presentation and treatment initiation for de novo metastatic breast cancer
10.1001/jamanetworkopen.2026.8908 · 2026
Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial
2021
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study
10.1016/s0140-6736(21)01789-x · 2021
Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011–2022
2025
Racial and ethnic disparities in receipt of ERBB2-targeted therapy for breast cancer, 2010-2020
10.1001/jamanetworkopen.2025.8086 · 2025
Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update
10.1200/jco.23.00933 · 2023
Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update
10.1200/jco.23.00933 · doi-reference
Racial and ethnic disparities in receipt of ERBB2-targeted therapy for breast cancer, 2010-2020
10.1001/jamanetworkopen.2025.8086 · doi-reference
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study
10.1016/s0140-6736(21)01789-x · doi-reference
Disparities in disease presentation and treatment initiation for de novo metastatic breast cancer
10.1001/jamanetworkopen.2026.8908 · doi-reference
Unconditional quantile regressions
10.3982/ecta6822 · doi-reference
Male-female wage differentials in urban labor markets
10.2307/2525981 · doi-reference
Controlling for frailty in pharmacoepidemiologic studies of older adults: validation of an existing Medicare claims-based algorithm
10.1097/ede.0000000000000833 · doi-reference
Socioeconomic status is associated with frailty: the Women’s Health and Aging Studies
10.1136/jech.2008.078428 · doi-reference
Using claims data to predict dependency in activities of daily living as a proxy for frailty
10.1002/pds.3719 · doi-reference
Race, breast cancer subtypes, and survival in the Carolina breast cancer study
10.1001/jama.295.21.2492 · doi-reference
Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting
10.1186/s13058-024-01902-w · doi-reference
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer
10.1038/s41523-023-00595-2 · doi-reference
Frailty in elderly people
10.1016/s0140-6736(12)62167-9 · doi-reference
Frailty in relation to the accumulation of deficits
10.1093/gerona/62.7.722 · doi-reference
Practical assessment and management of vulnerabilities in older patients receiving chemotherapy
10.1200/jco.2018.78.8687 · doi-reference
How not to neglect the care of elderly breast cancer patients?
10.1016/j.breast.2011.03.003 · doi-reference
The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: a population-based study in British Columbia from 2003 to 2013
10.1002/cncr.32631 · doi-reference
Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center
10.1007/s00432-020-03184-z · doi-reference
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008–2017 ESME cohort
10.1016/j.esmoop.2021.100114 · doi-reference